Physician profile
Stacey C Cox
NPI 1386980837
$2,961.26
in general payments reported to CMS, 2019-2025
31 companies · $963 in 2025
The $963 reported for 2025 was more than what 86% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $270 · 2022: $602 · 2023: $481 · 2024: $645 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,089.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $450.49 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $226.64 | 2022-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $218.65 | 2021-2024 | Gvoke Hypopen |
| Lilly USA, LLC | $189.15 | 2021-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $186.32 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.81 | 2022-2025 | Jardiance |
| Radius Health, INC. | $163.37 | 2023-2025 | Tymlos |
| Insulet Corporation | $130.28 | 2022-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $127.76 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $126.96 | 2024-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $124.90 | 2025 | |
| Dexcom, INC. | $124.42 | 2021-2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $112.07 | 2022-2025 | |
| Cequr Corporation | $110.87 | 2024-2025 | Cequr Simplicity |
| Abbvie INC. | $80.53 | 2021-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $67.51 | 2021-2025 | Xyosted |
| Alexion Pharmaceuticals, INC. | $41.29 | 2022-2025 | Strensiq |
| Ascensia Diabetes Care US INC. | $39.42 | 2024 | |
| Amneal Pharmaceuticals LLC | $37.05 | 2022-2023 | Unithroid |
| Astellas Pharma US INC | $25.48 | 2021 | |
| Bigfoot Biomedical INC | $25.15 | 2022 | |
| Medtronic, INC. | $24.04 | 2025 | Minimed 780g |
| Takeda Pharmaceuticals U.S.A., INC. | $22.11 | 2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $18.50 | 2025 | Farxiga |
| Ibsa Pharma INC. | $18.07 | 2023 | Tirosint, Licart |
| Almatica Pharma LLC | $17.48 | 2025 | Teriparatide |
| Zealand Pharma US, INC. | $17.21 | 2021 | |
| Merck Sharp & Dohme LLC | $16.74 | 2021 | |
| Exact Sciences Corporation | $16.54 | 2025 | Cologuard Collection Kit |
| Servier Pharmaceuticals LLC | $16.04 | 2022 | |
| Pfizer INC. | $14.41 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.